Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma

SIMPLE SUMMARY: Nowadays, there is no univocal therapeutical care for children with optic pathway gliomas (OPG): different chemotherapy regimens are proposed, but no one has clearly proved its superiority over the others on the PFS (Progression free survival). The efficacy of bevacizumab, an anti-VE...

Descripción completa

Detalles Bibliográficos
Autores principales: Calò, Pierluigi, Pianton, Nicolas, Basle, Alexandre, Vasiljevic, Alexandre, Barritault, Marc, Beuriat, Pierre Aurélien, Faure-Conter, Cécile, Leblond, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954224/
https://www.ncbi.nlm.nih.gov/pubmed/36831379
http://dx.doi.org/10.3390/cancers15041036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954224/
https://www.ncbi.nlm.nih.gov/pubmed/36831379
http://dx.doi.org/10.3390/cancers15041036

Ejemplares similares